12 results on '"Flach, Britta"'
Search Results
2. B Cell Depletion in HIV-1 Subtype A Infected Ugandan Adults: Relationship to CD4 T Cell Count, Viral Load and Humoral Immune Responses.
- Author
-
Oballah, Peter, Flach, Britta, Eller, Leigh A., Eller, Michael A., Ouma, Benson, Souza, Mark de, Kibuuka, Hannah N., Wabwire-Mangen, Fred, Brown, Bruce K., Michael, Nelson L., Robb, Merlin L., Montefiori, David, and Polonis, Victoria R.
- Subjects
- *
B cells , *HIV-positive persons , *HUMORAL immunity , *IMMUNE response , *VIRAL load , *COHORT analysis , *IMMUNOGLOBULINS - Abstract
To better understand the nature of B cell dysfunctions in subjects infected with HIV-1 subtype A, a rural cohort of 50 treatment-nai&vuml;e Ugandan patients chronically infected with HIV-1 subtype A was studied, and the relationship between B cell depletion and HIV disease was assessed. B cell absolute counts were found to be significantly lower in HIV-1+ patients, when compared to community matched negative controls (p,0.0001). HIV-1-infected patients displayed variable functional and binding antibody titers that showed no correlation with viral load or CD4+ T cell count. However, B cell absolute counts were found to correlate inversely with neutralizing antibody (NAb) titers against subtype A (p = 0.05) and subtype CRF02_AG (p = 0.02) viruses. A positive correlation was observed between subtype A gp120 binding antibody titers and NAb breadth (p = 0.02) and mean titer against the 10 viruses (p = 0.0002). In addition, HIV-1 subtype A sera showed preferential neutralization of the 5 subtype A or CRF02_AG pseudoviruses, as compared with 5 pseudoviruses from subtypes B, C or D (p,0.001). These data demonstrate that in patients with chronic HIV-1 subtype A infection, significant B cell depletion can be observed, the degree of which does not appear to be associated with a decrease in functional antibodies. These findings also highlight the potential importance of subtype in the specificity of cross-clade neutralization in HIV-1 infection. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
3. In vivo attenuation of recombinant murine gammaherpesvirus 68 (MHV-68) is due to the expression and immunogenicity but not to the insertion of foreign sequences
- Author
-
El-Gogo, Susanne, Flach, Britta, Staib, Caroline, Sutter, Gerd, and Adler, Heiko
- Subjects
- *
VIRUSES , *HEPATITIS C , *VIRAL hepatitis , *FLAVIVIRAL diseases - Abstract
Abstract: Recombinant herpesviruses are increasingly utilized to study herpesvirus biology. For recombinant viruses carrying insertions of foreign sequences, attenuated phenotypes in vivo have been frequently observed. In most cases, the underlying mechanisms were not clear or have not been investigated. In this study, we used a recombinant murine gammaherpesvirus 68 (MHV-68), carrying a cassette for the expression of the non-structural protein NS3 of Hepatitis C virus (MHV-68-NS3), to systematically address the question whether the insertion of a defined foreign sequence (NS3) interferes with the biological properties of the recombinant virus in vivo, and to analyze the underlying mechanism. We show that while MHV-68-NS3 is attenuated in vivo, recombinant MHV-68 carrying identical genomic inserts but unable to express the NS3 protein, are not attenuated. Moreover, we provide evidence that the attenuated phenotype of MHV-68-NS3 is caused by the immune response. Our findings are important for the in vivo use of recombinant MHV-68 carrying insertions of marker genes, reporter genes or genes of model antigens. They are also relevant for the potential application of MHV-68 as gene delivery vector. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
4. Non-HIV Vaccine-Induced Immune Responses as Potential Baseline Immunogenicity Predictors of ALVAC-HIV and AIDSVAX B/E-Induced Immune Responses.
- Author
-
Huang, Ying, Alam, Shomoita, Andersen-Nissen, Erica, Carpp, Lindsay N., Dintwe, One B., Flach, Britta S., Grunenberg, Nicole, Laher, Fatima, De Rosa, Stephen C., Ferrari, Guido, Innes, Craig, Bekker, Linda-Gail, Kublin, James G., McElrath, M. Juliana, Tomaras, Georgia D., Gray, Glenda E., and Gilbert, Peter B.
- Subjects
- *
HEPATITIS associated antigen , *AIDS vaccines , *TETANUS vaccines , *HEPATITIS B vaccines , *VACCINE effectiveness , *HEPATITIS B virus - Abstract
Identifying correlations between immune responses elicited via HIV and non-HIV vaccines could aid the search for correlates of HIV protection and increase statistical power in HIV vaccine-efficacy trial designs. An exploratory objective of the HVTN 097 phase 1b trial was to assess whether immune responses [focusing on those supported as correlates of risk (CoR) of HIV acquisition] induced via the RV144 pox-prime HIV vaccine regimen correlated with those induced via tetanus toxoid (TT) and/or hepatitis B virus (HBV) vaccines. We measured TT-specific and HBV-specific IgG-binding antibody responses and TT-specific and HBV-specific CD4+ T-cell responses at multiple time points in HVTN 097 participants, and we assessed their correlations at peak time points with HIV vaccine (ALVAC-HIV and AIDSVAX B/E)-induced responses. Four correlations were significant [false discovery rate-adjusted p-value (FDR) ≤ 0.2]. Three of these four were with IgG-binding antibody responses to TT measured one month after TT receipt, with the strongest and most significant correlation [rho = 0.368 (95% CI: 0.096, 0.588; p = 0.008; FDR = 0.137)] being with IgG-binding antibody responses to MN gp120 gDneg (B protein boost) measured two weeks after the second ALVAC-HIV and AIDSVAX B/E boost. The fourth significant correlation [(rho = 0.361; 95% CI: 0.049, 0.609; p = 0.021; FDR = 0.137)] was between CD4+ T-cell responses to a hepatitis B surface antigen peptide pool, measured 2 weeks after the third HBV vaccination, and IgG-binding antibody responses to gp70BCaseAV1V2 (B V1V2 immune correlate), measured two weeks after the second ALVAC-HIV and AIDSVAX B/E boost. These moderate correlations imply that either vaccine, TT or HBV, could potentially provide a moderately useful immunogenicity predictor for the ALVAC-HIV and AIDSVAX B/E HIV vaccine regimen. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Stochastic Interventional Vaccine Efficacy and Principal Surrogate Analyses of Antibody Markers as Correlates of Protection against Symptomatic COVID-19 in the COVE mRNA-1273 Trial.
- Author
-
Huang, Ying, Hejazi, Nima S., Blette, Bryan, Carpp, Lindsay N., Benkeser, David, Montefiori, David C., McDermott, Adrian B., Fong, Youyi, Janes, Holly E., Deng, Weiping, Zhou, Honghong, Houchens, Christopher R., Martins, Karen, Jayashankar, Lakshmi, Flach, Britta, Lin, Bob C., O'Connell, Sarah, McDanal, Charlene, Eaton, Amanda, and Sarzotti-Kelsoe, Marcella
- Subjects
- *
VACCINE effectiveness , *COVID-19 vaccines , *GEOMETRIC distribution , *COVID-19 , *IMMUNOGLOBULIN G , *IMMUNOGLOBULINS - Abstract
The COVE trial randomized participants to receive two doses of mRNA-1273 vaccine or placebo on Days 1 and 29 (D1, D29). Anti-SARS-CoV-2 Spike IgG binding antibodies (bAbs), anti-receptor binding domain IgG bAbs, 50% inhibitory dilution neutralizing antibody (nAb) titers, and 80% inhibitory dilution nAb titers were measured at D29 and D57. We assessed these markers as correlates of protection (CoPs) against COVID-19 using stochastic interventional vaccine efficacy (SVE) analysis and principal surrogate (PS) analysis, frameworks not used in our previous COVE immune correlates analyses. By SVE analysis, hypothetical shifts of the D57 Spike IgG distribution from a geometric mean concentration (GMC) of 2737 binding antibody units (BAU)/mL (estimated vaccine efficacy (VE): 92.9% (95% CI: 91.7%, 93.9%)) to 274 BAU/mL or to 27,368 BAU/mL resulted in an overall estimated VE of 84.2% (79.0%, 88.1%) and 97.6% (97.4%, 97.7%), respectively. By binary marker PS analysis of Low and High subgroups (cut-point: 2094 BAU/mL), the ignorance interval (IGI) and estimated uncertainty interval (EUI) for VE were [85%, 90%] and (78%, 93%) for Low compared to [95%, 96%] and (92%, 97%) for High. By continuous marker PS analysis, the IGI and 95% EUI for VE at the 2.5th percentile (519.4 BAU/mL) vs. at the 97.5th percentile (9262.9 BAU/mL) of D57 Spike IgG concentration were [92.6%, 93.4%] and (89.2%, 95.7%) vs. [94.3%, 94.6%] and (89.7%, 97.0%). Results were similar for other D29 and D57 markers. Thus, the SVE and PS analyses additionally support all four markers at both time points as CoPs. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial.
- Author
-
Gilbert, Peter B., Montefiori, David C., McDermott, Adrian B., Fong, Youyi, Benkeser, David, Deng, Weiping, Zhou, Honghong, Houchens, Christopher R., Martins, Karen, Jayashankar, Lakshmi, Castellino, Flora, Flach, Britta, Lin, Bob C., OÕConnell, Sarah, McDanal, Charlene, Eaton, Amanda, Sarzotti-Kelsoe, Marcella, Lu, Yiwen, Yu, Chenchen, and Borate, Bhavesh
- Subjects
- *
COVID-19 , *VACCINATION , *MESSENGER RNA , *IMMUNOGLOBULINS , *CLINICAL trials - Abstract
In the coronavirus efficacy (COVE) phase 3 clinical trial, vaccine recipients were assessed for neutralizing and binding antibodies as correlates of risk for COVID-19 disease and as correlates of protection. These immune markers were measured at the time of second vaccination and 4 weeks later, with values reported in standardized World Health Organization international units. All markers were inversely associated with COVID-19 risk and directly associated with vaccine efficacy. Vaccine recipients with postvaccination 50% neutralization titers 10, 100, and 1000 had estimated vaccine efficacies of 78% (95% confidence interval, 54 to 89%), 91% (87 to 94%), and 96% (94 to 98%), respectively. These results help define immune marker correlates of protection and may guide approval decisions for messenger RNA (mRNA) COVID-19 vaccines and other COVID-19 vaccines. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
7. Safety, Tolerability, and Pharmacokinetics of a Long-Acting Broadly Neutralizing Human Immunodeficiency Virus Type 1 (HIV-1) Monoclonal Antibody VRC01LS in HIV-1-Exposed Newborn Infants.
- Author
-
McFarland, Elizabeth J, Cunningham, Coleen K, Muresan, Petronella, Capparelli, Edmund V, Perlowski, Charlotte, Morgan, Patricia, Smith, Betsy, Hazra, Rohan, Purdue, Lynette, Harding, Paul A, Theron, Gerhard, Mujuru, Hilda, Agwu, Allison, Purswani, Murli, Rathore, Mobeen H, Flach, Britta, Taylor, Alison, Lin, Bob C, McDermott, Adrian B, and Mascola, John R
- Subjects
- *
NEWBORN infants , *HIV , *MONOCLONAL antibodies , *PHARMACOKINETICS , *INFANTS - Abstract
Background: Perinatal human immunodeficiency virus type 1 (HIV-1) continues to occur due to barriers to effective antiretroviral prevention that might be mitigated by long-acting broadly neutralizing monoclonal antibodies (bNAbs).Methods: An extended half-life bNAb, VRC01LS, was administered subcutaneously at 80 mg/dose after birth to HIV-1-exposed, nonbreastfed (cohort 1, n = 10) and breastfed (cohort 2, n = 11) infants. Cohort 2 received a second dose (100 mg) at 12 weeks. All received antiretroviral prophylaxis. VRC01LS levels were compared to VRC01 levels determined in a prior cohort.Results: Local reactions (all grade ≤2) occurred in 67% and 20% after dose 1 and dose 2, respectively. The weight-banded dose (mean 28.8 mg/kg) of VRC01LS administered subcutaneously achieved a mean (standard deviation) plasma level of 222.3 (71.6) µg/mL by 24 hours and 44.0 (11.6) µg/mL at week 12, prior to dose 2. The preestablished target of ≥50 µg/mL was attained in 95% and 32% at weeks 8 and 12, respectively. The terminal half-life was 37-41 days. VRC01LS level after 1 dose was significantly greater (P <.002) than after a VRC01 dose (20 mg/kg). No infants acquired HIV-1.Conclusions: VRC01LS was well tolerated with pharmacokinetics that support further studies of more potent long-acting bNAbs as adjunct treatment with antiretrovirals to prevent infant HIV-1 transmission. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
8. Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates.
- Author
-
Corbett, Kizzmekia S., Nason, Martha C., Flach, Britta, Gagne, Matthew, O’Connell, Sarah, Johnston, Timothy S., Shah, Shruti N., Edara, Venkata Viswanadh, Floyd, Katharine, Lai, Lilin, McDanal, Charlene, Francica, Joseph R., Flynn, Barbara, Wu, Kai, Choi, Angela, Koch, Matthew, Abiona, Olubukola M., Werner, Anne P., Moliva, Juan I., and Andrew, Shayne F.
- Subjects
- *
IMMUNITY , *MESSENGER RNA , *COVID-19 vaccines , *SARS-CoV-2 , *MUCOUS membranes , *VIRAL replication - Abstract
The article offers insight to a study analysing immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates.. It mentions that levels of serum and mucosal spike-specific IgG in mRNA-1273- vaccinated nonhuman primatess were inversely correlated with the reduction of viral replication in the upper airway and lower airway after SARS-CoV-2 challenge.
- Published
- 2021
- Full Text
- View/download PDF
9. Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants.
- Author
-
Pegu, Amarendra, O’Connell, Sarah E., Schmidt, Stephen D., O’Dell, Sijy, Talana, Chloe A., Lai, Lilin, Albert, Jim, Anderson, Evan, Bennett, Hamilton, Corbett, Kizzmekia S., Flach, Britta, Jackson, Lisa, Leav, Brett, Ledgerwood, Julie E., Luke, Catherine J., Makowski, Mat, Nason, Martha C., Roberts, Paul C., Roederer, Mario, and Rebolledo, Paulina A.
- Subjects
- *
SARS disease , *MESSENGER RNA , *COVID-19 vaccines , *VIRAL vaccines , *IMMUNE response - Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutations may diminish vaccine-induced protective immune responses, particularly as antibody titers wane over time. Here, we assess the effect of SARS-CoV-2 variants B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.429 (Epsilon), B.1.526 (Iota), and B.1.617.2 (Delta) on binding, neutralizing, and angiotensin-converting enzyme 2 (ACE2)Ð competing antibodies elicited by the messenger RNA (mRNA) vaccine mRNA-1273 over 7 months. Cross-reactive neutralizing responses were rare after a single dose. At the peak of response to the second vaccine dose, all individuals had responses to all variants. Binding and functional antibodies against variants persisted in most subjects, albeit at low levels, for 6 months after the primary series of the mRNA-1273 vaccine. Across all assays, B.1.351 had the lowest antibody recognition. These data complement ongoing studies to inform the potential need for additional boost vaccinations. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
10. Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19.
- Author
-
Doria-Rose, Nicole, Suthar, Mehul S., Makowski, Mat, O'Connell, Sarah, McDermott, Adrian B, Flach, Britta, Ledgerwood, Julie E, Mascola, John R, Graham, Barney S, Lin, Bob C, O'Dell, Sijy, Schmidt, Stephen D, Widge, Alicia T, Edara, Venkata-Viswanadh, Anderson, Evan J, Lai, Lilin, Floyd, Katharine, Rouphael, Nadine G, Zarnitsyna, Veronika, and Roberts, Paul C
- Subjects
- *
COVID-19 vaccines , *DENGUE hemorrhagic fever , *COVID-19 , *DIFFUSE large B-cell lymphomas , *IMMUNOGLOBULINS - Published
- 2021
- Full Text
- View/download PDF
11. A sensitive method to quantify HIV-1 antibodies in mucosal samples.
- Author
-
Prabhakaran, Madhu, Narpala, Sandeep, Andrews, Sarah F., O'Connell, Sarah, Lin, Chien L., Coates, Emily E., Flach, Britta, Ledgerwood, Julie E., and McDermott, Adrian B.
- Subjects
- *
HIV , *HIV antibodies , *VACCINE trials , *ENZYME-linked immunosorbent assay , *MUCOUS membranes - Abstract
Human immunodeficiency virus (HIV) remains a significant public health issue. In recent years, passive immunization with broadly neutralizing antibodies (bNabs) is being considered as a potentially efficacious approach for fighting HIV. One candidate that holds great promise is represented by the CD4-binding site targeted bNab capable of neutralizing over 90% of circulating HIV strains, VRC01. VRC01 along with its variants and clonal relatives – VRC01-LS and VRC07-523LS are currently being evaluated as vaccines in a number of clinical trials for HIV treatment and prevention. While mucosal areas of the body serve as major ports of HIV entry, reliable quantification of bNabs for pharmacokinetic and bioavailability analyses has been challenging due to low antibody concentrations in these samples. We developed an immunoassay on the Singulex platform which enables ultra-sensitive quantification of VRC01, VRC07, VRC01-LS and VRC07-523LS with a greater than 4-log linear dynamic range (LDR) and less than 120 pg/mL lower limit of quantitation (LLOQ). We implemented this assay to quantify VRC01 levels in rectal, cervical and oral mucosal samples in two passive immunization studies conducted with VRC01 – VRC 601 and VRC 602. Our assay was able to successfully quantify VRC01 levels in mucosal samples from all dosage groups (5 – –40 mg/kg) in these trials. VRC01 levels in a significant proportion of these samples (37% in oral and 25% in rectal mucosa) were below the lower limits of quantitation of other traditional immunoassays used for VRC01 quantification. We also measured VRC01 levels in sera from these trials and found that VRC01 measurements made using our assay exhibited excellent correlation (r2 = 0.9509) with measurements made previously using Enzyme-linked immunosorbent assay (ELISA). Our assay provides a reliable, sensitive and accurate method for quantification of clinically relevant bNabs and will help delineate antibody infiltration and bioavailability characteristics in complex biological matrices (CBM) such as mucosal tissues. This will in turn help determine clinical antibody threshold concentrations required to mediate protection against HIV acquisition and serve to inform dosing regimens and clinical trial design for future efficacy trials with these bNabs. • Development of an immunoassay that detects infused HIV mAbs at less than 120 pg/mL. • HIV antibody detected in oral, rectal and cervical mucosa from human infusion trials. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
12. The small noncoding RNAs (sncRNAs) of murine gammaherpesvirus 68 (MHV-68) are involved in regulating the latent-to-lytic switch in vivo.
- Author
-
Steer, Beatrix, Strehle, Martin, Sattler, Christine, Bund, Dagmar, Flach, Britta, Stoeger, Tobias, Haas, Jürgen G., and Adler, Heiko
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.